- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 10.07. | FDA, in policy shift, publishes some drug rejection letters | ||
| 10.07. | AbbVie to pay $700M for trispecific drug from Ichnos Glenmark | ||
| 10.07. | Renasant Bio, chasing drugs for ADPKD, raises $55M in seed funding | ||
| 09.07. | Lilly gets FDA OK of modified dosing for Alzheimer's drug | ||
| 09.07. | Merck to buy Verona Pharma and its lung drug in $10B deal | ||
| 09.07. | Gilead signs lenacapavir access deal; Arvinas CEO to step down | ||
| 09.07. | Actithera draws new investors to radiopharma drug pitch | ||
| 08.07. | Trump says pharmaceutical, copper tariffs coming 'very soon' | ||
| 08.07. | Novartis gets approval of first malaria medicine for newborns | ||
| 08.07. | Cargo agrees to Concentra buyout after trial setback, layoffs | ||
| 08.07. | Protein degraders: chasing undruggable targets | ||
| 07.07. | Medical groups, pregnant doctor sue RFK Jr. over vaccine changes | ||
| 07.07. | After delay, Kalvista wins FDA OK for drug to treat rare swelling disorder | ||
| 07.07. | Apogee touts positive data for atopic dermatitis drug | ||
| 07.07. | Study results boost Cogent's case for rare disease drug | ||
| 07.07. | [Podcast] Trial Trailblazers: Behind clinical breakthroughs | ||
| 02.07. | Regeneron bispecific approved for myeloma; Concentra to buy IGM | ||
| 02.07. | Organon drug for endometriosis falls short in mid-stage study | ||
| 02.07. | Acadia CEO sets sights on 'much more assertive' deals to invigorate pipeline | ||
| 01.07. | Atai and Beckley, set to merge, reveal study success for psychedelic drug | ||
| 01.07. | Sodium channel blockers for pain: New opportunities after Vertex's 'watershed' moment | ||
| 30.06. | Sage to lay off most staff amid Supernus buyout | ||
| 30.06. | Moderna flu shot outperforms marketed vaccines in large late-stage trial | ||
| 30.06. | AbbVie to buy CAR-T developer Capstan in deal worth up to $2.1B | ||
| 27.06. | FDA takes major step to ease access to CAR-T therapy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .